中国多中心基于人群的研究：乳腺神经内分泌癌与乳腺浸润性导管癌的临床特征和预后差异。
Differences in clinical characteristics and prognosis between breast neuroendocrine carcinoma and breast invasive ductal carcinoma: A multicentre population-based study from China.
机构信息
Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
出版信息
Cancer Med. 2023 Apr;12(8):9644-9649. doi: 10.1002/cam4.5819. Epub 2023 Mar 23.
AIM
We constructed a multicentre cohort in China to analyse the differences in clinical characteristics, treatment strategies and prognoses between breast neuroendocrine carcinoma (NEC) and invasive ductal carcinoma (IDC) of the breast.
METHODS
All patients with early-stage breast cancer who attended three hospitals in Beijing from 2000 to 2018 were included in the study. We used propensity score matching to make a 1:3 match between NEC and IDC.
RESULTS
After propensity score matching, 153 patients with IDC and 51 patients with NEC were analysed. Multivariate Cox regression showed that compared to patients with IDC, patients with NEC had a worse disease-free survival (HR = 2.94, 95% CI: 1.69-5.12, p < 0.001).
CONCLUSION
NEC patients have a worse disease-free survival than IDC patients.
目的
本研究构建了中国多中心队列，旨在分析乳腺神经内分泌癌（NEC）与乳腺浸润性导管癌（IDC）之间临床特征、治疗策略及预后的差异。
方法
选取 2000 年至 2018 年于北京 3 家医院就诊的早期乳腺癌患者，采用倾向性评分匹配法（1:3）对 NEC 和 IDC 进行匹配。
结果
倾向性评分匹配后，纳入 IDC 患者 153 例，NEC 患者 51 例。多因素 Cox 回归分析显示，与 IDC 患者相比，NEC 患者无病生存期更差（HR=2.94，95%CI：1.69-5.12，p<0.001）。
结论
NEC 患者无病生存期较 IDC 患者差。
Zotero 插件